STOCKHOLM, May 6 /PRNewswire/ -- Axelar AB today announced successful completion of the single-day oral dosing part of its ongoing phase I/II clinical trial on cancer patients with its new anti-cancer drug AXL1717,an insulin-like growth factor-1 (IGF-1) receptor inhibitor which has no effects on the closely related insulin receptor. The study is conducted in Sweden on patients having terminal cancer disease. The results showed that a single-day dosing of AXL1717 could be successfully escalated with excellent tolerability. No dose-limiting toxicity was reported. The next part of the trial has now been approved, including a seven-day dosing BID regimen instead of single-day BID treatments. The first patients have already been treated with AXL1717 for seven days.

REHOVOT, Israel, May 6 /PRNewswire/ -- D-Pharm announced today that it has submitted IND and Special Protocol Assessment (SPA) packages to the US Food and Drug Administration (FDA), for its pivotal Phase III clinical trial of DP-b99 in acute ischemic stroke patients. D-Pharm plans to initiate the trial later this year following FDA review of the IND and SPA. Recently, D-Pharm also obtained Scientific Advice from the European Medicines Agency (EMEA) on the development strategy for DP-b99 in Europe.

CASTRES, France, May 6 /PRNewswire/ -- Pierre Fabre Dermatologie, specialised department of Pierre Fabre Laboratories, is proud to announce the launch of a set of clinical trials following the signature of an exclusive and worldwide licence agreement on July 10th 2008 with the University of Bordeaux. The contract covers the development, production and marketing of a paediatric beta-blocker for the treatment of severe infantile haemangioma with the intention of obtaining NDA-approval (New Drug Application) both for Europe and the USA. Patents were also applied for in this indication.

CALGARY, Canada, May 6 /PRNewswire/ -- Addax Petroleum Corporation (TSX: AXC and LSE: AXC) (Addax Petroleum or the Corporation) will announce its financial results for the quarter ended March 31, 2009 on Wednesday, May 13, 2009, and will discuss its financial results in a conference call on Wednesday, May 13, 2009 at 11:00 a.m. Eastern Time / 4:00 p.m. London, U.K. time. Mr. Jean Claude Gandur, President and Chief Executive Officer, Mr. James Pearce, Chief Operating Officer, and Mr. Michael Ebsary, Chief Financial Officer, will discuss the Corporation's most recent financial and operating results.

LONDON, May 6 /PRNewswire/ --

Analog screening systems are gradually being replaced by digital mammography systems. Screening programmes for breast cancer detection are responsible for driving the market. A majority of screening programmes have already been implemented in European countries. However, in some others, implementation of these programmes is proceeding slowly but steadily, leading to the increased installation of mammography systems.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

LONDON, May 6 /PRNewswire/ -- Micro Focus is set to attain a leading position in the Automated Software Quality market, with recommended offers to acquire both Borland Software Corporation and a division of Compuware.

Stephen Kelly, Micro Focus Chief Exectuive, said the move was a very logical progression for the company and built on the products Micro Focus already offered in the testing space - a market valued at $2bn annually.

The deals will be part funded with a credit facility backed by HSBC, Barclays, Lloyds and RBS. The CEO defended the decision to stretch the company despite the economic backdrop:

CALGARY, Canada, May 6 /PRNewswire/ -- PENN WEST ENERGY TRUST (TSX - PWT.UN; NYSE - PWE) is pleased to announce its results for the first quarter ended March 31, 2009

TEL AVIV, Israel, May 6 /PRNewswire/ -- InspireMD, developers of MGuard(TM), announced today that the first patient has been enrolled in the iMOS registry. MGuard(TM) was successfully implanted at the General University Hospital in Prague; the procedure was performed by Dr. Jan Horak.

InspireMD plans to enroll 1000 'real world' Mguard(TM) patients. The registry, which is a post market study, will be conducted in Europe, Asia and South America. Data from the registry, an unselected heterogeneous population, will be used to support data from other clinical studies.

BEIJING, May 6 /PRNewswire/ --

Following the launch of the online check-in service on its Chinese website for flights departing from London and Stockholm international airports, Air China today launched the same service on the Company's U.K. and Sweden-based websites. At the end of April, this time-saving and convenient feature was enabled from the U.K. website for Air China operated flights departing from London Heathrow, and is to be followed by Stockholm-Arlanda Airport and the Swedish website in May.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080625/CNW017LOGO )

STOCKHOLM, May 6 /PRNewswire/ -- Jadestone Networks, the Nordic-based owner and operator of the multiplayer gaming networks DiceArena and GamArena, today announced that Betfair has agreed terms to become a distribution partner.

Betfair will integrate to the DiceArena gaming network after the summer where it will sit alongside existing Jadestone Networks' distribution partners such as bwin, Nordicbet, PAF and Gala Coral. The DiceArena network has seen steady growth since its hard launch in Q1 this year and together with the GamArena network has helped Jadestone to record a year on year increase in unique cash player numbers of an impressive 116%.